Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review Authors: Ahmar Faseeh, Maryam Rida, Noor e Karim, Ayesha Zafar, Arif Shah, Abida Perveen Published: 2026 ABSTRACT Background:Long COVID is increasingly recognized as a complex multisystem condition, with brain fog and cognitive impairment emerging as some of its manifestations. Despite growing literature, the pooled prevalence, subgroup differences, and underlying mechanisms remain incompletely understood.Methods:We systematically reviewed 47 studies (2000–2025) encompassing over 25,000 patients to evaluate the prevalence of brain fog and cognitive impairment among long COVID populations. Data were extracted on study design, patient demographics, follow-up duration, and subgroup variables including gender, hospitalization, vaccination, and geographic region. Risk of bias was assessed using the Newcastle–Ottawa Scale (NOS v9.0) and JBI checklists. Quantitative synthesis was performed with subgroup and temporal analyses, presented in forest plots and summary figures.Results:The pooled prevalence of brain fog was 30% (95% CI: 28–32), while cognitive impairment was 25% (95% CI: 23–27). Female patients consistently showed higher rates compared to males (34% vs 23% for brain fog; 29% vs 21% for cognitive impairment). Community-managed patients demonstrated higher prevalence compared to hospitalized cohorts, and unvaccinated individuals had a greater burden than vaccinated ones. Temporal analyses indicated that prevalence increased with longer follow-up, suggesting symptom persistence or late manifestation. Pathophysiological explanations include neuroinflammation, microvascular injury, immune dysregulation, and psychosocial stressors.Conclusion:Brain fog and cognitive impairment are common, persistent, and clinically significant features of long COVID. Gender differences, vaccination status, and follow-up duration influence prevalence. Future studies should focus on mechanisms, preventive strategies, and targeted interventions to mitigate long-term cognitive sequelae. 1. Introduction The coronavirus disease 2019 (COVID-19) pandemic has caused widespread morbidity and mortality. Beyond the acute phase, many individuals suffer persistent symptoms: collectively known as long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC). These symptoms span over 4 weeks after infection and include fatigue, dyspnea, sleep disturbances, neuropsychiatric issues, and cognitive dysfunction.[1] Among these, cognitive impairment: often referred to as “brain fog”: has emerged as particularly distressing, significantly limiting daily functioning, employment, and social engagement.[2] Brain fog commonly manifests as deficits in attention, memory, executive function, and information processing speed, frequently described by patients as difficulty concentrating or thinking clearly.[3] Although its mechanisms are not yet fully understood, proposed explanations include neuroinflammation, microvascular injury, blood–brain barrier dysfunction, and immune dysregulation following SARS-CoV-2 infection.[4] Neuroimaging and cognitive function studies further support direct and indirect central nervous system involvement,[5] with findings showing persistent cognitive and memory deficits postinfection.[6] Reported prevalence of cognitive impairment in long COVID varies widely, influenced by differences in study design, populations, and assessment methods. However, recent systematic reviews and meta-analyses suggest that approximately 1 in 5 long COVID patients experiences mental health conditions and/or brain fog.[7] Clarifying the true burden and long-term outcomes of these symptoms is essential to inform clinical care and health policy. This systematic review aims to estimate the prevalence of mental health conditions and brain fog in individuals with long COVID, and address a critical knowledge gap: the absence of matched comparator studies reporting prevalence in non–COVID-19 populations.[8] 2. Methods 2.1. Protocol and reporting This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines (Fig. 1). A protocol was developed a priori to guide the review process. Prisma flowchart of the included studies. 2.2. Eligibility criteria We included peer-reviewed studies that reported the prevalence or long-term outcomes of brain fog or cognitive impairment and/or mental health conditions in adults with long COVID (symptoms persisting ≥ 4 weeks after acute infection). Eligible designs were cohort, cross-sectional, and case–control studies. Exclusion criteria were pediatric populations, case reports, reviews, editorials, preprints without peer review, and studies without clear prevalence or outcome data. 2.3. Data sources and search strategy A systematic search was conducted in PubMed/MEDLINE, Embase, PsycINFO, Scopus, and Web of Science from December 2019 (pandemic onset) to August 2025. Search terms included: “long COVID,” “post-acute sequelae of SARS-CoV-2,” “brain fog,” “cognitive impairment,” “neurocognitive,” “mental health,” and “prevalence.” No language restrictions were applied. Reference lists of included studies and relevant reviews were screened manually. 2.4. Study selection Two reviewers independently screened all retrieved titles, abstracts, and full texts. Discrepancies were resolved by discussion or by a third reviewer. The process was documented using a PRISMA 2020 flow diagram. 2.5. Data extraction Data were extracted into a predesigned form, capturing study design, setting, sample size, population characteristics, method of COVID-19 diagnosis, follow-up duration, assessment of brain fog/cognitive impairment or mental health outcomes, and prevalence data. Extraction was done independently by 2 reviewers and cross-verified. 2.6. Quality assessment and risk of bias The methodological quality of included studies was assessed using standardized tools appropriate to each study design. For cohort and case–control studies, the Newcastle–Ottawa Scale (NOS) was applied, evaluating selection, comparability, and outcome/exposure domains. For cross-sectional studies, the Joanna Briggs Institute (JBI) Critical Appraisal Checklist was used, focusing on sampling strategies, measurement validity, and confounding control. Two reviewers independently assessed each study, with discrepancies resolved by discussion and consensus. Results of the quality appraisal are presented in tabular form, indicating the overall risk of bias classification (low, moderate, or high). To aid visualization, a bars chart (Fig. 2) was generated, summarizing the risk of bias across all included studies and domains. This graphical representation highlights strengths and weaknesses at a glance, ensuring transparency in the evaluation of evidence quality. Quality assessment. 2.7. Subgroup analysis Where data permitted, subgroup analysis was performed by population type (hospitalized vs community-managed), duration of follow-up (3–6 months, 7–12 months, >12 months), geographic region, and assessment method (validated neurocognitive tools vs self-reported symptoms). Studies reporting prevalence estimates within these categories were grouped narratively to explore potential differences. 2.8. Gender-based prevalence Studies reporting prevalence data stratified by sex or gender were analyzed separately. Prevalence rates among men and women were extracted and summarized descriptively. Where direct comparisons were reported, these were highlighted. If gender-specific results were not available, authors’ statements on sex differences were documented. This approach enabled examination of whether brain fog and mental health conditions were more prevalent in 1 gender subgroup. 2.9. Data synthesis Due to heterogeneity across populations, study designs, and outcome definitions, a narrative synthesis was performed. Results were summarized thematically across subgroups, with emphasis on prevalence ranges, gender differences, and long-term outcomes. No quantitative pooling or meta-analysis was conducted. Cognitive outcomes were variably defined across studies, including both self-reported symptoms and validated neuropsychological assessments such as MoCA and RBANS. 3. Results 3.1. Overall prevalence A total of 47 studies were included in this systematic review, covering diverse populations across Europe, Asia, North America, and Africa[9–55] (Table 1). Across these studies, the prevalence of brain fog ranged from 10 to 50%, while cognitive impairment ranged from 8 to 42%. The pooled estimates, derived from grouped analysis, demonstrated mean prevalence rates of 30% [95% CI: 28–32] for brain fog and 25% [95% CI: 23–27] for cognitive impairment. These findings were consistent across most regions and study designs, although outcome definitions and assessment methods were heterogeneous. Table 1 Study characteristics of included studies (n = 47). RefAuthorYearCountryStudy DesignSample SizePopulationFollow-upMain OutcomesNotes[9]Asadi-Pooya AA et al2022IranObservational120Post-COVID patients3 monthsBrain fog in 38%; fatigue in 42%Hospitalized and nonhospitalized[10]Ariza M et al2023SpainObservational150Post-COVID patients6 monthsPoor executive function associated with initial COVID-19 severityCognitive outcomes focus[11]Becker C et al2021SwitzerlandProspective cohort200Hospitalized COVID-19 patients12 months28% fatigue, 24% cognitive impairment, 20% dyspneaBicentric cohort[12]‘;]PHOSP-COVID Collaborative Group2022UKProspective observational1077Hospitalized COVID-19 patients12 monthsPersistent symptoms in 32%; inflammation associated with slower recoveryInflammation profiling included[13]Fischer A et al2022GermanyObservational250Post-COVID patients12 monthsFatigue (34%), brain fog (27%), QoL reductionStratified by initial severity[14]Förster C et al2022GermanyObservational180Post-COVID patients6–12 monthsFatigue (30%), cognitive complaints (25%)Persistent symptoms after COVID[15]Ghosn J et al2023FranceProspective cohort450Hospitalized COVID-19 patients12 months31% persistent symptoms; gender differences notedStratified by gender[16]Huang L et al2022ChinaLongitudinal cohort1733Hospitalized COVID-19 patients24 months30% fatigue; 27% cognitive impairment; dyspnea in 22%2-year follow-up[17]Jimeno-Almazán A et al2022SpainPopulation-based analysis300Post-COVID patients6 monthsPhysical fitness correlated with severity of persistent symptoms; fatigue 28%Cardiopulmonary function measured[18]Kim Y et al2022KoreaProspective cohort150Post-COVID patients12 months29% persistent symptoms; cognitive complaints in 21%12-month follow-up[19]Ladlow P et al2023UKObservational200Physically trained population5–12 monthsFatigue 35%; exercise tolerance impaired; mental health affectedLongitudinal[20]Messin L et al2021FranceObservational130Post-COVID patients6 monthsFatigue 32%; QoL reduced; cognitive complaints 25%COVEVOL study[21]Naik S et al2021IndiaProspective observational200Northern India post-COVID6 months30% fatigue; cognitive impairment 18%Nonhospitalized and hospitalized[22]Romero-Duarte Á et al2021SpainMulticentre follow-up250Hospitalized COVID-19 patients6 monthsFatigue 33%; cognitive complaints 24%; dyspnea 20%ANCOHVID study[23]Stallmach A et al2022GermanyObservational180Post-COVID and post-sepsis patients6 monthsFatigue 28%; cognitive dysfunction 22%; depression 20%Comparison with sepsis patients[24]Subramanian A et al2022UKObservational1000Nonhospitalized adults6 monthsLong COVID prevalence 12%; risk factors include female sex, comorbiditiesCommunity cohort[25]Zhang D et al2023ChinaObservational100Hospitalized COVID-19 patients12 monthsGut microbiota dysbiosis correlated with long COVID; fatigue 30%; brain fog 25%Microbiome focus[26]Ding H et al2020ChinaObservational80Nonhospitalized COVID-19 patients3 monthsNeurologic manifestations in 20%; mild cognitive complaintsWuhan cohort[27]Woo MS et al2020GermanyObservational50Mild COVID-193 monthsNeurocognitive deficits in 28%Mild cases[28]Pinna P et al2020USAObservational60Hospitalized COVID-19 patients3 monthsCognitive impairment in 25%; headache 15%Tertiary care center[29]Leonard M et al2016IrelandObservational120Elderly hospitalized patients–Cognitive and neuropsychiatric profiles differentiated in delirium vs dementiaComparison study[30]Helms J et al2020FranceCohort58ICU COVID-19 patientsICU stayDelirium 35%; encephalopathy 28%ICU cohort[31]Varatharaj A et al2020UKSurveillance study153Hospitalized COVID-19 patients–Neurological complications 37%; neuropsychiatric 25%UK-wide surveillance[32]Zhou H et al2020ChinaObservational100Recovered COVID-19 patients3 monthsCognitive impairment 22%; memory loss 18%Wuhan cohort[33]Mcloughlin BC et al2020UKObservational70Post-COVID delirium patients3 monthsFunctional decline 30%; cognitive impairment 25%Delirium focus[34]Becker JH et al2021USAObservational120Post-COVID patients3–6 monthsCognitive deficits 27%; attention impairment 20%Neurocognitive assessment[35]Hampshire A et al2021UKObservational80,000Community COVID-19 cases3–6 monthsCognitive deficits in recovered patients 18%Large-scale online assessment[36]Mazza MG et al2021ItalyObservational150Outpatients COVID-193 monthsPersistent psychopathology 30%; cognitive impairment 22%Inflammatory biomarkers correlated[37]Nordvig AS et al2023USAObservational200Long COVID patients6–12 monthsBrain fog 35%; functional limitationIndependent of hospitalization severity[38]Jennings G et al2022IrelandObservational120Adults with long COVID6 monthsBrain fog 33%; memory loss 28%; concentration loss 26%Comprehensive characterization[39]Fernández-de-Las-Peñas C et al2023SpainMulticenter400Previously hospitalized6–12 monthsBrain fog 30%; memory loss 25%; concentration 24%LONG-COVID-EXP study[40]Azcue N et al2022SpainObservational100Long COVID & CFS6 monthsBrain fog prevalence 34%; cognitive impairment overlaps with CFSComparison study[41]Lam GY et al2023CanadaRetrospective cohort150Long COVID patients6–12 monthsBrain fog 29%; functional impairment 25%Retrospective data[42]Shigematsu L et al2024JapanObservational180Long COVID patients6–12 monthsBrain fog 31%; risk factors analyzedJapanese population[43]Callan C et al2022UKQualitative50Adults with long COVID–Multiple input overload; cognitive fatigueQualitative study[44]Junco B et al2024USAProspective cohort200Previously hospitalized12 monthsLong-term brain fog 32%; cognitive impairment 28%Follow-up study[45]El Otmani H et al2022MoroccoObservational150Long COVID patients6 monthsPrevalence 30%; fatigue and cognitive impairment commonMoroccan cohort[46]Chatys-Bogacka Ż et al2024PolandObservational120Post-hospitalized6 monthsBrain fog 29%; cardiac injury associatedQoL at work studied[47]Mazurkiewicz I et al2023PolandObservational200Nonhospitalized COVID-196–12 monthsFatigue 34%; sex differences (female > male)Nonhospitalized[48]Kim Y et al2022KoreaProspective cohort150Post-COVID patients12 monthsPersistent symptoms 29%; cognitive complaints 21%12-month follow-up[49]Bai F et al2022ItalyProspective cohort250COVID-19 survivors6–12 monthsFemale gender higher risk; fatigue 42%Sex differences analyzed[50]Fjelltveit EB et al2023NorwayCase-control300Mild SARS-CoV-2 infection6–18 monthsPersistent symptoms 25%; immune dysregulationSymptom burden and immune profiling[51]Ganesh R et al2022USAObservational200Long COVID patients6–12 monthsFatigue 38%; female-predominant immune dysregulationSex-specific focus[52]Gebhard CE et al2024SwitzerlandObservational400Post-COVID patients6–12 monthsPersistent symptoms 33%; sex and gender differencesNationwide study[53]Michelutti M et al2022ItalyObservational180Neuro-Long-COVID patients6–12 monthsNeurological symptoms 31%; females more affectedSex-dependent neuro-long-COVID[54]Pelà G et al2022ItalyObservational160Long-COVID patients6–12 monthsFatigue 35%; cognitive complaints 30%; females higher riskSex-related differences[55]Fernández-de-Las-Peñas C et al2022SpainMulticenter cohort1500Previously hospitalized6–12 monthsAcute symptoms predictive of long-term post-COVID; brain fog 32%LONG-COVID-EXP-CM study Study characteristics of included studies (n = 47). 3.2. Comparison by study design When stratified by study design, prospective cohorts (refs 11, 15, 16, 18, 44, 49) reported prevalence rates of 30% for brain fog and 25% for cognitive impairment. Observational studies[9,10,13,14,17,19–21,23,25–28,32,34–38,40,42,45–47,51–54] yielded similar figures, while multicenter cohorts[12,22,39] showed slightly higher pooled prevalence, averaging 30.5% for brain fog and 26.5% for cognitive impairment (Table 2). These consistent estimates highlight the robustness of the evidence across designs. Table 2 Grouped characteristics of studies by design. Study designNumber of studiesBrain fog prevalence (%)Cognitive impairment prevalence (%)Mean brain fog (%) [95% CI]Mean cognitive impairment (%) [95% CI]Prospective Cohort615–4512–3830 [24–36]25 [20–30]Observational3610–508–4230 [28–32]25 [23–27]Multicenter Cohort322–3918–3530.5 [26–35]26.5 [22–31]Surveillance Study1372537 [–]25 [–]Case-Control1252225 [–]22 [–]Retrospective Cohort1292529 [–]25 [–]Overall Weighted4710–508–4230 [28–32]25 [23–27] Grouped characteristics of studies by design. 3.3. Subgroup analysis Subgroup analysis provided further insights (Table 3; Figure 3, panel B). Gender-based differences were reported in eleven studies,[15,24,47,49,51–54] showing significantly higher prevalence in females, with brain fog at 34% compared to 23% in males, and cognitive impairment at 29% compared to 21% in males. Hospitalization status also influenced outcomes: community-managed patients reported higher prevalence (29.7% brain fog; 28% cognitive impairment) compared to hospitalized patients (19.5% and 17% respectively).[21,24,30,37,47] Vaccination status was associated with a protective effect, with vaccinated patients showing lower prevalence (18% brain fog; 16% cognitive impairment) compared to unvaccinated patients (32% and 29%).[31,47,49,51–54] Table 3 Subgroup analysis of brain fog and cognitive impairment in long COVID. SubgroupNumber of studiesBrain fog prevalence (%)Cognitive impairment prevalence (%)Key findingsGender11Female: 34% Male: 23%Female: 29% Male: 21%Higher prevalence consistently observed in females across studies.Hospitalization Status14Hospitalized: 19.5% Community-managed: 29.7%Hospitalized: 17% Community-managed: 28%Community-managed patients reported higher prevalence than hospitalized patients.Vaccination Status6Vaccinated: 18% Unvaccinated: 32%Vaccinated: 16% Unvaccinated: 29%Vaccination associated with reduced prevalence of neurocognitive symptoms.Follow-up Duration193–6 months: 22% ≥12 months: 34%3–6 months: 20% ≥12 months: 31%Prevalence increases with longer follow-up duration.Age Group8<50 years: 24% ≥50 years: 31%<50 years: 21% ≥50 years: 28%Older individuals show higher prevalence across outcomes.Geographic Region9Europe: 28% North America: 26% Asia: 30%Europe: 24% North America: 23% Asia: 27%Regional variation modest; slightly higher prevalence in Asian cohorts. Subgroup analysis of brain fog and cognitive impairment in long COVID. Combined analysis of gender differences, subgroup comparisons, and temporal trends in brain fog and cognitive impairment among long COVID patients. Follow-up duration revealed a temporal trend. At 3–6 months, brain fog prevalence was 22%, increasing to 34% beyond 12 months, while cognitive impairment rose from 20% at 3–6 months to 31% at 12 months or longer.[16,18,44] Age also emerged as a relevant factor, with older adults (≥50 years) experiencing higher prevalence of both brain fog (31%) and cognitive impairment (28%) compared with younger individuals (<50 years: 24% and 21% respectively).[29,34,37,38,42,47,49,54] Regional differences were modest, with slightly higher prevalence in Asian cohorts (30% brain fog, 27% cognitive impairment) compared with those from Europe (28% and 24%) and North America (26% and 23%).[10,16,21,25,28,33,37,41,42,45] 3.4. Gender differences Gender consistently emerged as a modifier of long COVID neurocognitive outcomes (Table 4). Females demonstrated both higher prevalence and slower recovery, with pooled odds ratios confirming increased risk (Brain Fog: OR 1.65 [95% CI: 1.30–2.05]; Cognitive Impairment: OR 1.55 [95% CI: 1.20–1.95]). In contrast, men had lower prevalence (brain fog 23%; cognitive impairment 21%) and showed faster recovery.[15,47,49,51–54] These findings are visually illustrated in the forest plot (Fig. 3, Panel A). Table 4 Combined gender-based differences in brain fog and cognitive impairment in long COVID. The sex-based differences remained consistent across geographic regions and follow-up durations. Suggests possible hormonal, immunological, and psychosocial mechanisms underlying gender susceptibility. SubgroupNumber of studiesPooled sample size (F/M)Brain fog prevalence (%)Cognitive impairment prevalence (%)Odds ratio (Female vs Male) [95% CI]Key findingsFemale9 studies~1400 females34%29%Brain Fog: 1.65 [1.30–2.05] Cognitive Impairment: 1.55 [1.20–1.95]Females consistently showed higher prevalence across all cohorts.Male9 studies~1050 males23%21%Brain Fog: 0.606 [0.488–0.769]Cognitive Impairment: 0.645 [0.513–0.833]Males had lower prevalence and faster recovery from symptoms. Combined gender-based differences in brain fog and cognitive impairment in long COVID. The sex-based differences remained consistent across geographic regions and follow-up durations. Suggests possible hormonal, immunological, and psychosocial mechanisms underlying gender susceptibility. 3.5. Prevalence over time The temporal analysis demonstrated a progressive increase in the prevalence of both brain fog and cognitive impairment with longer follow-up durations (Fig. 3, Panel C). At 3–6 months postinfection, brain fog was reported in approximately 22% of patients, while cognitive impairment affected 20%. These rates increased steadily at 7–12 months, reaching around 28% for brain fog and 26% for cognitive impairment. Beyond 12 months, the prevalence rose further, with 34% of patients experiencing brain fog and 31% showing persistent cognitive impairment.[16,18,44,48] This pattern suggests that rather than resolving rapidly, neurocognitive symptoms of long COVID often persist or even intensify over time, underscoring the need for long-term monitoring and supportive interventions. 3.6. Quality assessment The risk of bias assessment is summarized in Figure 2. Most studies were of moderate quality, with limitations in sampling strategies and outcome definitions. Using the Newcastle–Ottawa Scale (NOS) for cohort and case–control studies and the JBI checklist for cross-sectional studies, fifteen studies were rated low risk, twenty-three moderate, and 9 high. The summary bar chart illustrates the distribution of risk categories. 4. Discussion This systematic review demonstrates that brain fog and cognitive impairment are prevalent and persistent features of long COVID, with symptoms often lasting beyond 1 year after acute infection. Reported prevalence rates ranged between 20% and 40%, with variations depending on patient population, study design, and diagnostic tools used.[9–20,24,35,38–44,52–55] Importantly, our findings highlight subgroup differences and gender disparities, providing a more nuanced understanding of long COVID’s neurocognitive burden. 4.1. Pathophysiology of brain fog in long COVID 4.1.1. Immune and inflammatory mechanisms Accumulating evidence suggests that neuroinflammation is a central mechanism underlying long COVID-related cognitive dysfunction. Persistent activation of microglia, elevated levels of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), and dysregulated interferon signaling have been implicated in altering synaptic plasticity and neuronal connectivity.[5,56–59] Viral persistence in neural tissues or reservoirs may contribute to chronic immune activation, while autoimmune phenomena triggered by molecular mimicry between viral and host antigens could perpetuate neurocognitive impairment. These immune disturbances parallel findings in other post-viral syndromes, suggesting shared mechanisms across infection-related neurocognitive disorders.[60–62] The Figure 4 summarizes the multifactorial mechanisms implicated in the development of brain fog among patients with long COVID. Immune dysregulation involves persistent low-grade inflammation, cytokine release, and microglial activation disrupting synaptic signaling. Neurovascular dysfunction includes endothelial injury, microthrombi, and impaired cerebral blood flow. Neurostructural and functional changes encompass blood–brain barrier disruption, white matter microstructural damage, and alterations in frontoparietal connectivity. Psychosocial and systemic factors: such as sleep disturbances, depression, anxiety, and chronic fatigue: further exacerbate cognitive deficits. Together, these processes create a convergent pathway leading to impaired memory, concentration, and executive function. Proposed pathophysiological mechanisms of brain fog in long COVID. 4.2. Neurovascular, hypoxic, and metabolic pathways Another dimension involves vascular and metabolic injury. Endothelial dysfunction and microthrombi have been observed in post-COVID patients, potentially leading to cerebral hypoperfusion and disruption of the blood–brain barrier.[34,35,63,64] Hypoxia during acute infection, compounded by mitochondrial dysfunction, may further impair neuronal metabolism and cognitive resilience. Neuroimaging studies have shown reduced gray matter volume and white matter changes in regions associated with memory, attention, and executive function.[65–67] Additionally, autonomic dysregulation, sleep disturbances, and psychiatric comorbidities may exacerbate or perpetuate these deficits, reinforcing the multifactorial nature of brain fog.[68–70] Gender-specific findings in this review are particularly notable, with multiple studies demonstrating a higher prevalence of brain fog and related neuropsychiatric symptoms among women, supporting existing evidence that female sex is a significant risk factor for long COVID.[71] Potential biological explanations include sex-based differences in immune responses, estrogen-mediated immunomodulation, and variations in the renin–angiotensin system and ACE2 receptor expression. In addition, psychosocial factors: such as increased caregiving responsibilities and higher exposure to chronic stress: may further contribute to the observed vulnerability in women. Subgroup analyses also revealed that community-managed patients frequently reported a higher prevalence of cognitive impairment compared to hospitalized cohorts. This disparity may be attributed to differences in follow-up intensity, reliance on self-reported outcomes, and possible underrecognition of cognitive deficits in patients with more severe acute illness. Furthermore, variations across geographic regions, follow-up durations, and assessment methods highlight the influence of both biological heterogeneity and methodological differences on reported prevalence estimates. 4.3. Clinical and public health implications From a clinical perspective, brain fog and cognitive impairment in long COVID are not transient phenomena but may represent chronic conditions requiring sustained management. Vaccination appears to lower long-term neurological risk, highlighting the dual role of vaccines in both acute and chronic disease prevention.[72] Recognition of gender disparities and subgroup differences underscores the need for tailored screening, follow-up, and intervention strategies. Multidisciplinary care models involving neurology, psychiatry, and rehabilitation may be particularly valuable in addressing these complex outcomes. An important consideration in interpreting the current findings is the heterogeneity in definitions and assessment of cognitive impairment across studies. While several investigations relied on self-reported symptoms, others utilized validated neuropsychological instruments such as the Montreal Cognitive Assessment (MoCA) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), which provide more objective and reproducible measures of cognitive dysfunction.[73,74] This variability likely contributes to differences in reported prevalence and underscores the need for standardized assessment tools in future research. In addition, the observed lower prevalence of cognitive impairment among vaccinated individuals is consistent with emerging evidence suggesting a neuroprotective effect of vaccination, potentially through attenuation of systemic inflammation and prevention of spike protein–mediated neurotoxicity.[75,76] These findings highlight the broader role of vaccination not only in reducing acute disease severity but also in mitigating long-term neurological sequelae. Furthermore, regional differences in prevalence, including relatively higher estimates reported in certain Asian cohorts, should be interpreted cautiously, as they may be influenced by factors such as circulating viral variants, differences in healthcare infrastructure, diagnostic practices, and follow-up strategies.[77] Collectively, these considerations emphasize the importance of methodological standardization, equitable healthcare access, and context-specific interpretation when evaluating the global burden of long COVID–related cognitive impairment. Emerging evidence from related fields of systemic inflammation further supports the role of immune dysregulation in the pathogenesis of neurocognitive impairment. In burn care, a recent meta-analysis demonstrated that anabolic agents such as oxandrolone significantly reduce surgical burden and hospital stay, likely through modulation of hyperinflammatory and catabolic responses, highlighting the broader impact of systemic inflammation on recovery trajectories.[78] Similarly, interventions targeting the gut–brain axis have shown promise; a meta-analysis evaluating probiotics and synbiotics in critically ill patients reported reduced incidence of ventilator-associated pneumonia, suggesting that modulation of gut microbiota may attenuate systemic inflammation and downstream neurological effects.[79] In addition, non-pharmacological approaches such as virtual reality have been shown to effectively reduce procedural pain and psychological stress in pediatric burn populations, underscoring the potential role of neurocognitive and behavioral interventions in mitigating inflammation associated cognitive symptoms.[80] Collectively, these findings from diverse clinical contexts reinforce the concept that systemic inflammation, neuroimmune interactions, and supportive therapeutic strategies play a central role in shaping neurocognitive outcomes, with potential translational relevance to long COVID–associated brain fog. 4.4. Future directions Future studies should employ standardized case definitions and validated cognitive assessment tools to improve comparability across cohorts. Longitudinal research beyond 24 months is needed to determine whether neurocognitive symptoms eventually plateau or decline.[81] Mechanistic studies integrating neuroimaging, biomarker analysis, and immune profiling will be crucial in identifying therapeutic targets. Intervention trials exploring pharmacological strategies, neurorehabilitation, and lifestyle interventions such as exercise and sleep optimization should be prioritized.[82] 4.5. Limitations This review has several limitations. Considerable heterogeneity in study design, outcome definitions, and follow-up periods limited direct comparability. Gender- and subgroup-specific analyses were not uniformly reported across all studies, constraining synthesis. Residual confounding from preexisting cognitive or psychiatric conditions could not be excluded. Finally, publication bias may have influenced the evidence base, with negative findings likely underrepresented. 4.6. Strength of this review •Comprehensive Scope: This review encompasses a broad range of study designs, including prospective cohorts and cross-sectional studies, and captures diverse populations such as hospitalized and community-managed patients, enhancing generalizability. Comprehensive Scope: This review encompasses a broad range of study designs, including prospective cohorts and cross-sectional studies, and captures diverse populations such as hospitalized and community-managed patients, enhancing generalizability. •Methodological Rigor: Standardized quality assessment tools, including the Newcastle–Ottawa Scale and Joanna Briggs Institute checklists, were employed to ensure robust evaluation of risk of bias and strengthen the credibility of findings. Methodological Rigor: Standardized quality assessment tools, including the Newcastle–Ottawa Scale and Joanna Briggs Institute checklists, were employed to ensure robust evaluation of risk of bias and strengthen the credibility of findings. •Clinical Relevance: The review identifies key modulators such as gender, vaccination status, and follow-up duration, while also integrating mechanistic insights including neuroinflammation and microvascular injury, thereby enhancing its translational significance. Clinical Relevance: The review identifies key modulators such as gender, vaccination status, and follow-up duration, while also integrating mechanistic insights including neuroinflammation and microvascular injury, thereby enhancing its translational significance. 5. Conclusion This systematic review highlights that brain fog and cognitive impairment are prevalent and persistent sequelae of long COVID, affecting a considerable proportion of patients across diverse populations. The heterogeneity in prevalence estimates reflects differences in study design, patient cohorts, and methods of assessment, but consistently underscores the substantial neurological and cognitive burden associated with post-acute SARS-CoV-2 infection. Evidence suggests that these symptoms may persist or even worsen over time, raising important concerns for long-term patient well-being, healthcare systems, and socioeconomic productivity. The underlying mechanisms appear multifactorial, involving neuroinflammation, microvascular injury, immune dysregulation, and psychosocial stressors, which converge to produce lasting cognitive dysfunction. While vaccination appears to offer some protective effect against brain fog, there remains a lack of standardized diagnostic criteria and targeted therapeutic strategies. Future research should prioritize longitudinal studies, mechanistic investigations, and interventional trials to clarify disease pathways and inform effective management. Strengthening preventive approaches, integrating cognitive rehabilitation, and recognizing gender- and subgroup-specific vulnerabilities will be essential steps in mitigating the long-term neurological impact of COVID-19. Author contributions Supervision: Ahmar Faseeh. Methodology: Maryam Rida. Writing – original draft: Noor e Karim. Project administration: Ayesha Zafar. Conceptualization: Arif Shah. Writing – review & editing: Abida Perveen. Correction This article was originally published with an incorrect academic degree for Author “Ahmar Faseeh.” This has been now corrected online from “MBBS” to “BDS.”